Status:
UNKNOWN
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
Lead Sponsor:
The People's Hospital of Leshan
Collaborating Sponsors:
Jiangsu HengRui Medicine Co., Ltd.
Conditions:
Ovarian Cancer
Chemotherapeutic Toxicity
Eligibility:
FEMALE
18-75 years
Phase:
PHASE2
Brief Summary
The study is evaluated the effacy and safety of apatinib combined with chemotherapy in the advanced ovarian cancer
Detailed Description
Ovarian cancer and fallopian tube cancer are common gynecological malignancies in our country. Ovarian cancer ranks the second in the incidence of gynecologic malignancies. The mortality rate is the h...
Eligibility Criteria
Inclusion
- Pathologically diagnosed as epithelial ovarian cancer, fallopian tube cancer, stage II-IV period, the expected survival of\> 6 months;
- ECOG \<2;
- Liver and kidney function is normal;
- No uncontrollable high blood pressure, bleeding, perforation, obstruction.
Exclusion
- Serious cardiopulmonary insufficiency, can not tolerate chemotherapy;
- Pregnant or lactating women;
- 3 years have occurred in other tumors (cervical cancer in situ, has cured basal cell carcinoma, except for bladder epithelial tumors);
- Allergic to apatinib or its accessories.
Key Trial Info
Start Date :
August 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT03393507
Start Date
August 1 2017
End Date
December 1 2019
Last Update
January 16 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhang xuan
Leshan, Sichuan, China, 600000